|
Market Closed -
Toronto S.E.
23:00:00 17/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 2.640 CAD | +0.76% |
|
-4.69% | +101.53% |
Company Valuation: Cardiol Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 142 | 43.96 | 71.77 | 151 | 130.4 | 308.4 | - | - |
| Change | - | -69.05% | 63.28% | 110.34% | -13.65% | 136.58% | - | - |
| Enterprise Value (EV) 1 | 142 | 43.96 | 36.84 | 120.4 | 108.9 | 293.4 | 298.2 | 308.4 |
| Change | - | -69.05% | -16.19% | 226.78% | -9.5% | 169.31% | 1.62% | 3.44% |
| P/E | -3.19x | -1.41x | -2.5x | -3.63x | -3.36x | -8.41x | -9.32x | -41.6x |
| PBR | - | - | 2.55x | 6.18x | 6.41x | 15x | 27.5x | - |
| PEG | - | 0x | 0.2x | -0.2x | 0.1x | 0.4x | 0.96x | 0.5x |
| Capitalization / Revenue | 1,803x | - | - | - | - | - | 313x | 5.85x |
| EV / Revenue | 1,803x | - | - | - | - | - | 303x | 5.85x |
| EV / EBITDA | -4.74x | -1.07x | -1.25x | -3x | -3.18x | -11.4x | -18.8x | -15x |
| EV / EBIT | -3.67x | -1.06x | -1.24x | -2.99x | -3.17x | -8x | -8.58x | -49x |
| EV / FCF | -6.03x | - | -1.46x | -4.8x | -4.56x | -8.59x | -10.9x | -4.77x |
| FCF Yield | -16.6% | - | -68.5% | -20.8% | -21.9% | -11.6% | -9.19% | -21% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.73 | -0.49 | -0.44 | -0.51 | -0.39 | -0.314 | -0.2834 | -0.0635 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 0.0788 | - | - | - | - | - | 0.9842 | 52.75 |
| EBITDA 1 | -29.95 | -41.12 | -29.54 | -40.11 | -34.21 | -25.72 | -15.88 | -20.62 |
| EBIT 1 | -38.66 | -41.34 | -29.79 | -40.28 | -34.32 | -36.66 | -34.76 | -6.288 |
| Net income 1 | -31.64 | -30.93 | -28.13 | -36.68 | -33.82 | -36.31 | -36.46 | -15.29 |
| Net Debt 1 | - | - | -34.93 | -30.58 | -21.42 | -15.01 | -10.26 | - |
| Reference price 2 | 2.330 | 0.690 | 1.100 | 1.850 | 1.310 | 2.640 | 2.640 | 2.640 |
| Nbr of stocks (in thousands) | 60,954 | 63,703 | 65,247 | 81,603 | 99,514 | 116,823 | - | - |
| Announcement Date | 3/23/22 A | 3/28/23 A | 4/1/24 A | 3/31/25 A | 3/31/26 A | - | - | - |
1CAD in Million2CAD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.41x | - | -11.41x | - | 220M | |
| 31.85x | 5.73x | 17.17x | 1.02% | 46.18B | |
| 34.7x | 3.34x | 14.42x | -.--% | 44.35B | |
| -20.15x | 232.19x | -21.56x | -.--% | 42.21B | |
| 46.3x | 5.35x | 29.28x | -.--% | 40.19B | |
| 27.32x | 7.86x | 20.08x | 0.42% | 29.83B | |
| 34.98x | 5.74x | 26.08x | -.--% | 17.17B | |
| 25.63x | 2.2x | 9.55x | 1.04% | 15.32B | |
| 28.8x | 1.89x | 11.64x | -.--% | 13.09B | |
| Average | 22.34x | 33.04x | 10.58x | 0.31% | 27.62B | |
| Weighted average by Cap. | 24.96x | 43.57x | 12.24x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CRDL Stock
- Valuation Cardiol Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
